Last reviewed · How we verify

NCT05446493

Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

Completed Phase 4 Last updated 6 July 2022
What this trial tests

Phase 4 trial testing Tadalafil 5mg in Erectile Dysfunction in 60 participants. Completed in 5 January 2022.

Timeline
1 April 2019
Primary endpoint
15 March 2021
5 January 2022

Quick facts

Lead sponsorAswan University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment60
Start date1 April 2019
Primary completion15 March 2021
Estimated completion5 January 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Aswan University

Who can join

Adults 30 to 70, male only, with Erectile Dysfunction or Erectile Dysfunction With Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this current study is to estimate serum level of YKL-40, serum total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tadalafil 5mg

Trials testing the same drug.

Other recruiting trials for Erectile Dysfunction

Currently open trials in the same condition.

Other Aswan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05446493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing